{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:08:20Z","timestamp":1747390100802},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272929"],"award-info":[{"award-number":["82272929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01420-3","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:59:01Z","timestamp":1729004341000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review"],"prefix":"10.1007","volume":"15","author":[{"given":"Ya-Zhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Zhen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Xiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"1420_CR1","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"key":"1420_CR2","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270\u20131. https:\/\/doi.org\/10.1056\/NEJMc1509660.","journal-title":"N Engl J Med"},{"key":"1420_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"key":"1420_CR4","doi-asserted-by":"publisher","first-page":"785400","DOI":"10.3389\/fimmu.2021.785400","volume":"12","author":"Y Ye","year":"2021","unstructured":"Ye Y, Zheng S. Successful immunotherapy for pancreatic cancer in a patient with TSC2 and SMAD4 mutations: a case report. Front Immunol. 2021;12:785400. https:\/\/doi.org\/10.3389\/fimmu.2021.785400.","journal-title":"Front Immunol"},{"key":"1420_CR5","doi-asserted-by":"publisher","first-page":"1016647","DOI":"10.3389\/fimmu.2022.1016647","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Case report: anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: a case and literature review. Front Immunol. 2022;13:1016647. https:\/\/doi.org\/10.3389\/fimmu.2022.1016647.","journal-title":"Front Immunol"},{"key":"1420_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030540","author":"A Forschner","year":"2020","unstructured":"Forschner A, et al. MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12030540.","journal-title":"Cancers"},{"key":"1420_CR7","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.Ccr-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3133.","journal-title":"Clin Cancer Res"},{"key":"1420_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.Ccr-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23:1920\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1741.","journal-title":"Clin Cancer Res"},{"key":"1420_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543\u201352. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3676.","journal-title":"JAMA Oncol"},{"key":"1420_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejca.2022.05.042","volume":"172","author":"CG Kim","year":"2022","unstructured":"Kim CG, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387\u201399. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.042.","journal-title":"Eur J Cancer"},{"key":"1420_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2021.7049","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Pancreatic cancer progression in a patient with lynch syndrome receiving immunotherapy: a cautionary tale. J Natl Compr Canc Netw. 2021;19:883\u20137. https:\/\/doi.org\/10.6004\/jnccn.2021.7049.","journal-title":"J Natl Compr Canc Netw"},{"key":"1420_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park HJ, et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021;4: e211136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1136.","journal-title":"JAMA Netw Open"},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586\u201397. https:\/\/doi.org\/10.1200\/jco.21.01497.","journal-title":"J Clin Oncol"},{"key":"1420_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","volume":"39","author":"K Bi","year":"2021","unstructured":"Bi K, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021;39:649-661.e645. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.015.","journal-title":"Cancer Cell"},{"key":"1420_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102429","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, et al. Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment predictive biomarkers and treatment outcomes. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14102429.","journal-title":"Cancers"},{"key":"1420_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070677","author":"A Di Federico","year":"2021","unstructured":"Di Federico A, et al. Hacking pancreatic cancer: present and future of personalized medicine. Pharmaceuticals. 2021. https:\/\/doi.org\/10.3390\/ph14070677.","journal-title":"Pharmaceuticals"},{"key":"1420_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ejso.2022.12.006","volume":"49","author":"R De Luca","year":"2023","unstructured":"De Luca R, et al. Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS\u00ae and neoadjuvant treatment. Eur J Surg Oncol. 2023;49:542\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2022.12.006.","journal-title":"Eur J Surg Oncol"},{"key":"1420_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00262-023-03366-x","volume":"72","author":"A Rizzo","year":"2023","unstructured":"Rizzo A, et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother. 2023;72:1381\u201394. https:\/\/doi.org\/10.1007\/s00262-023-03366-x.","journal-title":"Cancer Immunol Immunother"},{"key":"1420_CR19","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdx178.","journal-title":"Ann Oncol"},{"key":"1420_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000488","volume":"4","author":"M Aoki","year":"2019","unstructured":"Aoki M, et al. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open. 2019;4: e000488. https:\/\/doi.org\/10.1136\/esmoopen-2019-000488.","journal-title":"ESMO Open"},{"key":"1420_CR21","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624.","journal-title":"Clin Cancer Res"},{"key":"1420_CR22","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"1420_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092448","author":"M Peng","year":"2023","unstructured":"Peng M, Ying Y, Zhang Z, Liu L, Wang W. Reshaping the pancreatic cancer microenvironment at different stages with chemotherapy. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15092448.","journal-title":"Cancers"},{"key":"1420_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3892\/or.2017.5399","volume":"37","author":"T Doi","year":"2017","unstructured":"Doi T, et al. The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017;37:1545\u201354. https:\/\/doi.org\/10.3892\/or.2017.5399.","journal-title":"Oncol Rep"},{"key":"1420_CR25","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/jco.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354. https:\/\/doi.org\/10.1200\/jco.2011.36.5742.","journal-title":"J Clin Oncol"},{"key":"1420_CR26","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padron","year":"2022","unstructured":"Padron LJ, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377. https:\/\/doi.org\/10.1038\/s41591-022-01829-9.","journal-title":"Nat Med"},{"key":"1420_CR27","doi-asserted-by":"publisher","first-page":"100972","DOI":"10.1016\/j.xcrm.2023.100972","volume":"4","author":"J Du","year":"2023","unstructured":"Du J, et al. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: a biomolecular exploratory, phase II trial. Cell Rep Med. 2023;4:100972. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100972.","journal-title":"Cell Rep Med"},{"key":"1420_CR28","first-page":"88","volume":"1","author":"M Shadfan","year":"2012","unstructured":"Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res. 2012;1:88\u20139.","journal-title":"Transl Cancer Res"},{"key":"1420_CR29","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1073\/pnas.0508476103","volume":"103","author":"S Francoz","year":"2006","unstructured":"Francoz S, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A. 2006;103:3232\u20137. https:\/\/doi.org\/10.1073\/pnas.0508476103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1420_CR30","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.febslet.2009.07.021","volume":"583","author":"K Okamoto","year":"2009","unstructured":"Okamoto K, Taya Y, Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett. 2009;583:2710\u20134. https:\/\/doi.org\/10.1016\/j.febslet.2009.07.021.","journal-title":"FEBS Lett"},{"key":"1420_CR31","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.4161\/cc.8.23.10089","volume":"8","author":"F Mancini","year":"2009","unstructured":"Mancini F, Moretti F. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle. 2009;8:3854\u20139. https:\/\/doi.org\/10.4161\/cc.8.23.10089.","journal-title":"Cell Cycle"},{"key":"1420_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102420118","author":"AM Klein","year":"2021","unstructured":"Klein AM, et al. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2102420118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1420_CR33","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.Can-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng W, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res. 2012;72:5209\u201318. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-1187.","journal-title":"Cancer Res"},{"key":"1420_CR34","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","volume":"282","author":"C Schindler","year":"2007","unstructured":"Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282:20059\u201363. https:\/\/doi.org\/10.1074\/jbc.R700016200.","journal-title":"J Biol Chem"},{"key":"1420_CR35","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1172\/JCI68189","volume":"123","author":"JD Waight","year":"2013","unstructured":"Waight JD, et al. Myeloid-derived suppressor cell development is regulated by a STAT\/IRF-8 axis. J Clin Invest. 2013;123:4464\u201378. https:\/\/doi.org\/10.1172\/JCI68189.","journal-title":"J Clin Invest"},{"key":"1420_CR36","doi-asserted-by":"publisher","first-page":"8776","DOI":"10.1038\/sj.onc.1205993","volume":"21","author":"M Kadakia","year":"2002","unstructured":"Kadakia M, Brown TL, McGorry MM, Berberich SJ. MdmX inhibits Smad transactivation. Oncogene. 2002;21:8776\u201385. https:\/\/doi.org\/10.1038\/sj.onc.1205993.","journal-title":"Oncogene"},{"key":"1420_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4161\/cc.3.4.746","volume":"3","author":"M Wunderlich","year":"2004","unstructured":"Wunderlich M, Ghosh M, Weghorst K, Berberich SJ. MdmX represses E2F1 transactivation. Cell Cycle. 2004;3:472\u20138.","journal-title":"Cell Cycle"},{"key":"1420_CR38","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540-1554.e1512. https:\/\/doi.org\/10.1016\/j.cell.2016.11.022.","journal-title":"Cell"},{"key":"1420_CR39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.molcel.2017.05.011","volume":"66","author":"J Oyler-Yaniv","year":"2017","unstructured":"Oyler-Yaniv J, et al. Catch and release of cytokines mediated by tumor phosphatidylserine converts transient exposure into long-lived inflammation. Mol Cell. 2017;66:635-647.e637. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.011.","journal-title":"Mol Cell"},{"key":"1420_CR40","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1039\/c6cc01226d","volume":"52","author":"C Hoppmann","year":"2016","unstructured":"Hoppmann C, Wang L. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53-Mdm4. Chem Commun. 2016;52:5140\u20133. https:\/\/doi.org\/10.1039\/c6cc01226d.","journal-title":"Chem Commun"},{"key":"1420_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41420-019-0157-7","volume":"5","author":"L Jiang","year":"2019","unstructured":"Jiang L, Malik N, Acedo P, Zawacka-Pankau J. Protoporphyrin IX is a dual inhibitor of p53\/MDM2 and p53\/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Cell Death Discov. 2019;5:77. https:\/\/doi.org\/10.1038\/s41420-019-0157-7.","journal-title":"Cell Death Discov"},{"key":"1420_CR42","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/acs.jmedchem.9b00993","volume":"63","author":"P Sang","year":"2020","unstructured":"Sang P, et al. \u03b1-helix-mimicking sulfono-\u03b3-AApeptide inhibitors for p53-MDM2\/MDMX protein-protein interactions. J Med Chem. 2020;63:975\u201386. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00993.","journal-title":"J Med Chem"},{"key":"1420_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202100394","volume":"17","author":"X Zheng","year":"2021","unstructured":"Zheng X, et al. De novo nano-erythrocyte structurally braced by biomimetic Au(I)-peptide skeleton for MDM2\/MDMX predation toward augmented pulmonary adenocarcinoma immunotherapy. Small. 2021;17: e2100394. https:\/\/doi.org\/10.1002\/smll.202100394.","journal-title":"Small"},{"key":"1420_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","volume":"22","author":"A Sasaki","year":"2019","unstructured":"Sasaki A, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793\u2013802. https:\/\/doi.org\/10.1007\/s10120-018-00922-8.","journal-title":"Gastric Cancer"},{"key":"1420_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.21037\/tlcr-22-171","volume":"11","author":"S Cao","year":"2022","unstructured":"Cao S, et al. A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. Transl Lung Cancer Res. 2022;11:607\u201316. https:\/\/doi.org\/10.21037\/tlcr-22-171.","journal-title":"Transl Lung Cancer Res"},{"key":"1420_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175171","author":"HC Yildirim","year":"2022","unstructured":"Yildirim HC, et al. Blood based biomarkers as predictive factors for hyperprogressive disease. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11175171.","journal-title":"J Clin Med"},{"key":"1420_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447\u201362. https:\/\/doi.org\/10.1038\/nrc.2016.54.","journal-title":"Nat Rev Cancer"},{"key":"1420_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368. https:\/\/doi.org\/10.1038\/nri3175.","journal-title":"Nat Rev Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01420-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:13:06Z","timestamp":1729005186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01420-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01420-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethical Committee of Zhongshan Hospital affiliated to Fudan University. All the experimental protocol for involving human data was in accordance with the guidelines of our institutional Declaration of Helsinki in the manuscript, and written informed consent from the study patient was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of this case report and any accompanying images was obtained from the patient\u2019s legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"560"}}